Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.5 HKD | +0.98% | +12.55% | +18.71% |
08:55am | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.71% | 1.13B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-18.56% | 29.48B | |
+57.86% | 25.43B | |
-17.65% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech : Henlius Biotech Unit Wins FDA Nod to Start Clinical Trials of Solid Tumor Drug in US